G

Global Research Management, Inc. | Glendale, CA

Research site

(Unclaimed)

Location

1510 S Central Avenue Suite 300, Glendale, California, United States of America

Site insights

Top conditions

Top treatments

AMDX-2011P

AR-15512

INV-102

T4032

AZR-MD-001

Systane

STN1013600

TL-925

Lumigan

Tavilermide

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 10 total trials

A Phase 3 Study to Evaluate AZR-MD-001 in Patients With Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

This study is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study designed to evaluate the treatment of abnormal meibo...

Enrolling

Dry Eye Disease

Other: Vehicle

Drug: AZR-MD-001

New

A Study of AMDX-2011P in Participants With Alzheimer's Disease

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P...

Enrolling

Alzheimer Disease

Drug: AMDX-2011P

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 880 subjects with modera...

Active, not recruiting

Dry Eye Disease

Drug: TL-925

Other: Placebo

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis

Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to vehicle during 1-week dosing in participants with Acute In...

Enrolling

Acute Infectious Keratoconjunctivitis

Drug: INV-102

Drug: Vehicle

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 \[0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q...

Active, not recruiting

Glaucoma Open-Angle Primary

Ocular Hypertension

Drug: Timolol 0.5%

Drug: H-1337 Placebo